Key result
Treatment with 17b-estradiol or the ERα agonist 16α-LE2 slowed the progression of myocardial hypertrophy and reduced systolic dysfunction, but significantly decreased the 9-week survival rate to 58.3% compared to 92.3% with placebo.
Why the study?
Does estrogen, an ERα agonist, or raloxifene improve cardiac hypertrophy and function in a mouse model of pressure overload?
Does estrogen, an ERα agonist, or raloxifene improve cardiac hypertrophy and function in a mouse model of pressure overload?
Answers are grounded in this paper and cite their sources.
E2 and the ERα agonist 16α-LE2 attenuated the progression of myocardial hypertrophy and systolic dysfunction in a pressure overload mouse model, but were associated with significantly increased mortality.
The aim of this study was to investigate the effects of 17β-estradiol (E2), the selective ERα agonist 16α-LE2, and the selective estrogen receptor modulator (SERM) raloxifene on remodeling processes during the development of myocardial hypertrophy (MH) in a mouse model of pressure overload. Myocardial hypertrophy in ovariectomized female C57Bl/6J mice was induced by transverse aortic constriction (TAC). Two weeks after TAC, placebo treated mice developed left ventricular hypertrophy and mild systolic dysfunction. Estrogen treatment, but not 16α-LE2 or raloxifene reduced TAC induced MH compared to placebo. E2, 16α-LE2 and raloxifene supported maintenance of cardiac function in comparison with placebo. Nine weeks after induction of pressure overload, MH was present in all TAC groups, most pronounced in the raloxifene treated group. Ejection fraction (EF) was decreased in all animals. However, 16α-LE2 treated animals showed a smaller reduction of EF than animals treated with placebo. E2 and 16α-LE2, but not raloxifene diminished the development of fibrosis and reduced the TGFβ and CTGF gene expression. Treatment with E2 or 16α-LE2 but not with raloxifene reduced survival rate after TAC significantly in comparison with placebo treatment. In conclusion, E2 and 16α-LE2 slowed down the progression of MH and reduced systolic dysfunction after nine weeks of pressure overload. Raloxifene did not reduce MH but improved cardiac function two weeks after TAC. However, raloxifene was not able to maintain EF in the long term period.
No takes yet. Share an insight, caveat, or question.
Westphal et al. (2012) studied Pressure overload induced cardiac hypertrophy (n=52). 17b-estradiol (E2) and 16a-LE2 vs. Placebo was evaluated on Survival rate at 9 weeks (p=<0.05). Treatment with 17b-estradiol or the ERα agonist 16α-LE2 slowed the progression of myocardial hypertrophy and reduced systolic dysfunction, but significantly decreased the 9-week survival rate to 58.3% compared to 92.3% with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: